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Incomplete APOBEC3G/F neutralization by a defective HIV-1Vif protein can promote genetic diversification by inducing G-
to-Amutations in the HIV-1 genome. The HIV-1 Env V3 loop, critical for coreceptor usage, contains several putative
APOBEC3G/F target sites. Here, we determined if APOBEC3G/F, in the presence of Vif-defective HIV-1 virus, can induce G-to-A
mutations at V3 positions critical to modulation of CXCR4 usage. Peripheral bloodmononuclear cells (PBMC) andmonocyte-
derived macrophages (MDM) from 2HIV-1-negative donors were infected with CCR5-using 81.A-VifWT virus (i.e., with wild-
type [WT] Vif protein), 81.A-VifE45G, or 81.A-VifK22E (known to incompletely/partially neutralize APOBEC3G/F). The rate of
G-toAmutations was zero or extremely low in 81.A-VifWT- and 81.A-VifE45G-infected PBMC from both donors. Conversely, G-
to-A enrichment was detected in 81.A-VifK22E-infected PBMC (prevalence ranging from 2.18% at 7 days postinfection [dpi] to
3.07% at 21 dpi in donor 1 and from 10.49% at 7 dpi to 8.69% at 21 dpi in donor 2). A similar scenario was found inMDM. G-
to-Amutations occurred at 8 V3 positions, resulting in nonsynonymous amino acid substitutions. Of them, G24E and E25K
strongly correlated with phenotypically/genotypically defined CXCR4-using viruses (P 0.04 and 5.5e7, respectively) and in-
creased the CXCR4 N-terminal binding affinity for V3 (WT,40.1 kcal/mol; G24E,510 kcal/mol; E25K,522 kcal/mol). The
analysis of paired V3 and Vif DNA sequences from 84 HIV-1-infected patients showed that the presence of a Vif-defective virus
correlated with CXCR4 usage in proviral DNA (P 0.04). In conclusion, incomplete APOBEC3G/F neutralization by a single Vif
amino acid substitution seeds a CXCR4-using proviral reservoir. This can have implications for the success of CCR5 antagonist-
based therapy, as well as for the risk of disease progression.
APOBEC3 is an important component of the cellular innateimmunity against exogenous and endogenous retroviruses
(1). Several members of the APOBEC3 family (A to H) show
different degrees of antiviral potency, with APOBEC3G and
APOBEC3F generally regarded as exerting the strongest HIV-1
restriction in peripheral blood mononuclear cells (PBMC) and in
monocyte-derived-macrophages (MDM), respectively (2–5).
APOBEC3G/F proteins are packaged into HIV-1 virions and
associate with the reverse transcription (RT) complex. There, they
deaminate cytosine residues to uracil in the single-stranded DNA
minus strand, resulting in proviral guanosine-to-adenosine (G-
to-A) nucleotide mutations in the plus-strand DNA (6, 7). These
mutations predominantly occur in a GG or GA dinucleotide con-
text, which are the preferential (but not exclusive) target sites for
APOBEC3G and APOBEC3F, respectively (2, 6). Previous studies
have shown that the frequency of G-to-A nucleotide mutations
increases over the genome in the 5=-to-3= direction, with the low-
est frequency in the 5= long terminal repeat and the highest in the
5= portion of the nef gene sequence (6). Beyond G-to-A mutations,
C-to-T nucleotide mutations in plus-strand DNA have also been
described (6).
The activity of APOBEC3G/F is generally counteracted by the
HIV-1 regulatory protein Vif by promoting proteasome-depen-
dent APOBEC3G/F degradation (8) and inhibiting packaging in
the producer cell (9). However, the activity of Vif against
APOBEC3G/F is not absolute. Indeed, some Vif mutants fail (to
different extents) to neutralize these enzymes (2, 10–13). For in-
stance, previous in vitro studies showed that in the presence of the
Vif amino acid substitution K22E, Vif completely loses the ability
to neutralize APOBEC3G (implying APOBEC3G editing of the
viral genome) and retains partial activity against APOBEC3F (im-
plying less editing of APOBEC3F than APOBEC3G). In the pres-
ence of the Vif amino acid substitution E45G, Vif retained weak
activity against APOBEC3G (implying a low rate of APOBEC3G
editing) and completely neutralized APOBEC3F activity (imply-
ing no or limited APOBEC3F editing) (2).
Previous studies have shown that these two Vif amino acid
substitutions can facilitate the emergence of the G-to-A mutation
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at the HIV-1 RT position 184, which is associated with lamivudine
resistance (M184I) (14). It has been postulated that the predom-
inant effect of APOBEC3G-driven rather than APOBEC3F-driven
cytidine deamination reflects the impairment of these Vif mutants
(K22E and E45G) to efficiently neutralize the deamination activity
of APOBEC3G rather than APOBEC3F (14).
In the presence of other HIV-1 variants with suboptimal Vif
activity, the limited APOBEC3G/F-driven editing may also con-
tribute to genetic diversity and thus benefit the virus by facilitating
escape from other antiretroviral drugs (such as rilpivirine or thy-
midine analogues) and also cellular immunity (11, 12, 15–19).
HIV-1 sequences carrying the genetic footprints of past deamina-
tion events have been detected in treated and untreated chroni-
cally infected patients (20, 21), vertically infected infants (22), and
long-term nonprogressors (23), suggesting that variations in Vif
activity against APOBEC3G/F can occur in many different clinical
settings.
Among the different domains of HIV-1 gp120, the V3 loop is
recognized as the primary determinant for HIV-1 coreceptor us-
age (24–26). The V3 loop contains several putative APOBEC3G/F
target sites, including positions 24 and 25, which are known to be
critical for coreceptor usage (Fig. 1) (27–35). Recent studies sup-
posed a role of APOBEC3 proteins in inducing G-to-A nucleotide
mutations in the V3 region (3, 31). However, those studies were
limited to in silico observations or to investigation of members
of the APOBEC3 family other than APOBEC3G/F (such as
APOBEC3D).
Based on ultradeep 454 pyrosequencing (UDPS), we recently
suggested a role for APOBEC3G in inducing G-to-A nucleotide
mutations in the V3 region of a CXCR4-using strain (NL4.3) with
mutations at Vif positions 22 and 45 (36). These results provided
the rationale to investigate whether K22E and E45G in Vif can
affect the burden of G-to-A nucleotide mutations at V3 positions
critical for CXCR4 usage in a pure CCR5-using virus, such as 81.A,
thus facilitating the genetic evolution from CCR5 to CXCR4 co-
receptor usage. In order to also support this hypothesis in vivo, we
investigated the correlation of Vif variability with coreceptor us-
age in a set of 84 matched Vif/V3 sequences from HIV-1 subtype
B-infected patients.
MATERIALS AND METHODS
Cells. PBMC and MDM were obtained from the blood of healthy serone-
gative donors by separation over a Ficoll-Hypaque gradient. PBMC were
seeded in a T25 flask (Costar) at a density of 1.0 106 cells/ml in RPMI
1640 supplemented with 100 U/ml penicillin plus 100 g/ml streptomy-
cin, 2 mM L-glutamine, and 10% fetal bovine serum (FBS) in addition to
2g/ml of phytohemagglutinin (PHA; Sigma) and 50 U/ml recombinant
interleukin-2 (IL-2; Peprotech). In order to prepare MDM, PBMC were
resuspended in RPMI 1640 medium supplemented with 20% FBS and
then seeded into 48-well plates (1.8  106 cells/well). After 5 days, non-
adherent cells were carefully removed by repeated washings. The number
of MDM was estimated to be 105/well at the time of infection. Adherent
cells obtained using this technique generally consisted of pure differenti-
ated MDM (upon cytofluorimetric analysis, more than 95% of cells were
CD14 CD4 CD3). HEK-293T cells, generously donated by M. Zazzi,
were grown in a 37°C humidified atmosphere containing 5% CO2, using
complete Dulbecco’s modified Eagle’s medium (DMEM; Life Technolo-
gies, Inc., Gaithersburg, MD) supplemented with 10% fetal bovine serum.
Plasmids and transfection. The CCR5-using HIV-1 p81.A plasmid
(obtained from Bruce Chesebro [37–40] and gently provided by A. Cara)
was used in all of the experiments. The characteristics and genomic se-
quence of this strain have been previously described (41). HIV-1 Vif
amino acid substitutions K22E and E45G, known to reduce Vif activity
against APOBEC3G/F (2, 14), were introduced into the p81.A wild-type
backbone by site-directed mutagenesis (QuikChange II XL site-directed
mutagenesis kit, Agilent) according to the manufacturer’s instructions.
Plasmid DNA was further isolated by using the Qiaprep plasmid midiprep
kit (Qiagen). HEK-293T cells were plated in 6-well plates (200,000 cells/
well) 24 h before transfection. On the day of transfection, cell confluence
was approximately 70 to 80%. The different plasmids used for the study
were transfected using the Xtremegene 9 reagent (Roche) according to the
manufacturer. At day 3 posttransfection, the viruses were harvested
and filtered, and aliquots were stored at 80°C. In order to quantify
the viral particle amounts, supernatants were analyzed for p24 produc-
tion by using a commercial enzyme-linked immunosorbent assay kit
(Ag-Genscreen HIV-1 assay; Bio-Rad) according to the manufactur-
er’s instructions.
Virus infection in primary cells. In order to evaluate the editing ac-
tivity of APOBEC3G/F in human primary cells, stimulated PBMC and
MDM were infected with 10,000 pg/ml of p24 for 2 h of adsorption. Then,
cells were extensively washed to remove any residual viral particles, resus-
pended in complete medium (1 ml), and cultured on 48-well plates for 21
days (PBMC) or 28 days (MDM). In the case of PBMC, samples were
cocultivated every 7 days with new stimulated PBMC (500,000 cells/well)
from different donors. Every 7 days, both cells and supernatants were
harvested and stored at20°C and80°C. Virus growth was monitored
at all times postinfection by measuring supernatant p24 levels, as de-
scribed above. Sequencing of the proviral Vif region at the end of each
infection revealed maintenance of the specific Vif mutations.
In order to extract viral nucleic acids from both PBMC and MDM,
infected cells were harvested, and after gently washing with warm phos-
phate-buffered saline they were counted, dry pelleted, and stored at
20°C. Experiments were performed at least in triplicate, using two dif-
ferent HIV-seronegative donors.
Ultradeep V3 pyrosequencing. (i) Nucleic acid extraction. HIV-1
DNA was extracted from each cellular pellet by using the QIAamp blood
DNA minikit (Qiagen, Courtaboeuf, France).
FIG 1 Nucleotide and amino acid sequences of the V3 loop of the 81.A virus.
GG or GA motifs are underlined. V3 positions 11, 24, and 25 (known to impact
HIV-1 coreceptor usage) are shown in gray boxes.
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(ii) Pyrosequencing. UDPS was performed using a 454 GS Junior
pyrosequencing system. A 367-nucleotide (nt) fragment that included the
V3 env region (nt 901 to 1,005 of the HIV-1 p81.A gp120 env gene, corre-
sponding to V3 amino acids [aa] 1 to 32) was generated by nested PCR
using a bar code-modified primer after a first amplification under the
following conditions: 1 cycle of 94°C for 3 min, 30 cycles of 94°C for 30 s,
54°C for 30 s, and 72°C for 35 s, and a final extension at 72°C for 7 min. For
this first amplification we used the forward primer V3S10, 5=-CCAATTC
CCATACATTATTGT-3= (nt 649 to 669 of the HIV-1 p81.A gp120 env
gene), and the reverse primer V3AS5, 5=-CTTCTCCAATTGTCCCTC
A-3= (nt 1421 to 1439).
For UDPS, a nested PCR was performed with the following primers:
inner forward primer V3S5, 5=-GTTAAATGGCAGTCTAGCAG-3= (nt
790 to 814), and reverse primer V3AS1, 5=-GAAAAATTCCCCTCCACA
ATT-3= (nt 1138 to 1158). Nested PCR was performed with the Fast Start
HiFi PCR system (Roche Diagnostics, Mannheim, Germany) under the
following conditions: 1 cycle of 94°C for 3 min, 30 cycles of 94°C for 30 s,
67°C for 30 s, and 72°C for 35 s, and a final extension at 72°C for 7 min.
The amplified products were purified using Agencourt AMPure PCR pu-
rification beads (Beckman Coulter, Brea, CA) and quantified with the
Quant-iT PicoGreen double-stranded DNA assay kit (Life Technologies,
Eugene, OR, USA) on a GloMax multidetection system (Promega, Mad-
ison, WI, USA). Pooled PCR products were clonally amplified on cap-
tured beads in water-oil emulsion microreactors. A total of 500,000 DNA-
enriched samples were deposited in the wells of a full GS Junior Titanium
PicoTiterPlate device and pyrosequenced in both the forward and reverse
directions. The 200 nucleotide cycles were performed in a 10-h sequenc-
ing run. Phylogenetic analyses excluded any possibly of sample contami-
nation (data not shown). For each run, a maximum of 5 samples (includ-
ing a plasmid control) were loaded to ensure adequate coverage of
sequences.
(iii) Bioinformatic analyses of V3 sequences. The V3 env region se-
quences obtained after 454 pyrosequencing were demultiplexed and
quantified using the SFF tool (Roche). By using a home-made Perl script
that utilizes a BLAST algorithm, all reads were checked for homology with
reference strains (80%), and the orientation was discerned (42). After
this filtering, SHORAH package 0.5.1 (43) was used to correct sequences
for homopolymeric region-associated errors. Subsequently, the sequences
were clustered, taking into account read redundancy and forward/reverse
directions, using the Exonerate 2.2.0 package, and aligned against the
plasmid reference using the Needleman-Wunsch algorithm (EMBOSS
package) (44–46). The final alignments were manually checked for inser-
tions or deletions in the homopolymeric region that would result in a
frameshift. Nucleotidic variants were evaluated and quantified with a
home-made Perl script.
(iv) Sensitivity of UDPS for detecting minor V3 env variants. The
frequency of errors resulting from V3 amplification and deep sequencing
was assessed for the 5 plasmid controls used. The mismatch nucleotide
error rate was very low after sequencing correction (0.006% for each
plasmid). Furthermore, considering only the variants covered in both
orientations in more than 5 reads, we did not find a mismatch in the
plasmid controls examined; thus, only variants with these characteristics
were considered reliable for the analyses. To evaluate the linkage of vari-
ants in each sequence, only reads covering the entire HIV-1 V3 env region
were considered.
HIV-1 tropism determination of V3 sequences obtained by UDPS.
(i) In silico analyses. V3 sequences with at least one amino acid substi-
tution induced by a G-to-A deamination event (obtained in previous
experiments) were first submitted to the geno2pheno algorithm (http:
//coreceptor.geno2pheno.org/) to evaluate the false-positive rate (FPR)
and the related HIV coreceptor usage. The G-to-A-induced amino acid
substitutions, conferring a reduction of the FPR compared to 81.A-VifWT,
were further investigated for their association with a dual/pure CXCR4
tropism in vivo by using an independent data set of 251 HIV-1 subtype
B RNA samples obtained for routine clinical practice. For each sample,
coreceptor usage was determined both phenotypically (by using the
enhanced sensitivity version of Trofile) and genotypically (by V3 se-
quencing followed by using the geno2pheno prediction set at an FPR
of 10%) (47). The prevalence of G-to-A-induced amino acid substitu-
tions was determined for 192 V3 sequences reported to be CCR5 tropic
by both genotypic and phenotypic tests and 59 V3 sequences reported
to be pure CXCR4 tropic or dual/mixed tropic by the enhanced sensi-
tivity version of Trofile and confirmed CXCR4 tropic by a genotypic
tropism test. Chi-square tests of independence were performed to
identify statistically significant differences between the 2 groups of
samples.
Finally, a structural analysis was also performed to evaluate the impact
of these G-to-A-induced amino acid substitutions on CCR5 or CXCR4
recognition, according to methods described elsewhere (36, 48). Detailed
information about our methodology is available in Text S1 in the supple-
mental material.
(ii) In vitro analysis. In the in vitro experiments, we focused on V3
amino acid substitutions conferring an FPR of10% (which was used as
a threshold to infer CXCR4 coreceptor usage). These amino acid substi-
tutions were first introduced in the p81.A wild-type backbone by site-
directed mutagenesis, as reported in the previous section. Viral stocks
obtained after transfection were used to infect the PM1 cell line, which
predominantly expresses the CCR5 coreceptor, and the C8166 cell line,
which exclusively expresses the CXCR4 coreceptor (49). Wild-type 81.A
and NL4.3 viruses were used as controls.
PM1 and C8166 were infected with 20,000 pg/ml of HIV-1 p24 with an
overnight adsorption step. Then, cells were extensively washed to remove
any residual viral particles, resuspended in complete medium (1 ml), and
cultured on 48-well plates for 10 days in triplicate. HIV-1 replication was
estimated 10 days postinfection by measuring the p24 released into cul-
ture supernatants. NL4.3 and 81.A were used as controls for C8166 and
PM1 cell infection, respectively.
In vivo correlation between the presence of Vif-defective isolates
and non-CCR5 usage in proviral DNA. The correlation between the
presence of a defective Vif and CXCR4 usage was assessed by analyzing
paired Vif and V3 proviral DNA sequences obtained from PBMC of 84
HIV-1 subtype B-infected patients under suppressive, highly active
antiretroviral therapy (HAART; patients with a viral load of50 cop-
ies/ml). In accordance with the European Guidelines, an FPR set at
20% by the geno2pheno algorithm was used to infer HIV tropism (47).
The protocol for V3 population sequencing has been previously de-
scribed (50), while the protocol for Vif population sequencing is re-
ported in Text S2 in our supplemental material. A Vif protein was
considered defective if it contained any stop codon or at least one
substitution at the following amino acid positions described in the
literature as impairing Vif activity: 21, 22, 32, 38, 40, 45, 69, 108, 115,
138, 139, 150, 114, and 133 (2, 11, 14, 51, 52). HIV-1 DNA quantifi-
cation was performed according to the methodology described in ref-
erence 50. The correlation between the presence of a defective Vif and
CXCR4 usage was analyzed with the chi-square test of independence
and a two-by-two contingency table. The correlation between the pres-
ence of a defective Vif and the amount of HIV-1 DNA (expressed in
copies per 106 cells) was analyzed by using the Mann-Whitney test.
RESULTS
Viral replication of 81.A strains with Vif variants in human pri-
mary cells. We first evaluated the replication capacity of the
CCR5-using 81.A-VifWT, 81.A-VifK22E, and 81.A-VifE45G viruses
by measuring the amount of p24 released in culture supernatants
at different time points postinfection. 81.A-VifWT replicated with
mean ( standard deviation [SD]) p24 production ranging from
12,296 4,748 pg/ml at 7 days to 7,849,353 5,767,237 pg/ml at
21 days postinfection in PBMC from donor 1, and from 85,371
20,722 pg/ml at 7 days to 294,968  14,088 pg/ml at 21 days
postinfection in PBMC from donor 2 (Fig. 2A and B). Similar
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results were obtained for MDM, with a mean SD p24 produc-
tion ranging from 88,459 3,522 pg/ml at 7 days to 1,090,044
809,661 pg/ml at 28 days postinfection from donor 1 and from
97,867 6,879 pg/ml at 7 days to 442,188 148,422 pg/ml at 28
days postinfection from donor 2 (Fig. 2C and D).
While the replication characteristics of 81.A-VifE45G were com-
parable to those observed for 81.A-VifWT, a remarkable decrease
in HIV replication capacity was observed in PBMC infected with
81.A-VifK22E. Indeed, 81.A-VifK22E replicated with a mean p24
production ranging from 1,387 238 pg/ml at 7 days to 457.5
72 pg/ml at 21 days postinfection from donor 1 and from 938 
405 pg/ml at 7 days to 129  29 pg/ml at 21 days postinfection
from donor 2 (Fig. 2A and B). An attenuated defect in viral repli-
cation capacity was observed in MDM infected with 81.A-VifK22E,
with mean p24 production ranging from 84,217 2,999 pg/ml at
7 days to 68,286  58,147 pg/ml at 28 days postinfection from
donor 1 and from 1,201  157 pg/ml at 7 days to 10,419  833
pg/ml at 28 days postinfection from donor 2 (Fig. 2C and D). The
replication profiles of Vif mutants 81.A-VifK22E and 81.A-VifE45G
were superimposable to those observed by Mulder et al. (14).
The expression levels of APOBEC3G and APOBEC3F were
confirmed by Western blotting in both PBMC and MDM (see Fig.
S1 in the supplemental material). Overall, these data suggested
that single-nucleotide mutations affecting Vif activity can inter-
fere with viral fitness at endogenous APOBEC3G/F expression
levels in both PBMC and MDM.
HIV-1 Vif mutants and overall sequence diversity in V3.
By using UDPS, the mean ( SD) number of V3 sequences
obtained after infection was 16,641  1,164 for PBMC and
12,614 723 for MDM.
Overall, the median number of G-to-A nucleotide mutations
detected in V3 sequences by UDPS was 1 (range, 0 to 2). In par-
ticular, no V3 nucleotide substitutions were detected in HIV-1
DNA from 81.A-VifWT-infected PBMC (carrying a functional Vif
gene) for either donor (Table 1). Similarly, an extremely low
rate of nucleotide variations (exclusively due to non-
APOBEC3G-related mutations) was detected in 81.A-VifE45G-
infected PBMC (Table 1). A different scenario was observed in
PBMC infected with 81.A-VifK22E (which fails to completely
neutralize APOBEC3G and, partially, APOBEC3F). In particu-
lar, V3 sequences with at least one G-to-A nucleotide mutation
were detected at each time point postinfection, with a preva-
lence ranging from 2.07% to 3.07% in donor 1 and from 6.37%
to 10.49% in donor 2. These mutations accounted for 95.96%
of V3 mutated sequences.
Similarly, V3 sequences with nucleotide substitutions were not
detected in 81.A-VifWT-infected MDM and with a very low prev-
alence in 81.A-VifE45G-infected MDM (all corresponding to non-
APOBEC3-related mutations) (Table 1). Conversely, in 81.A-
VifK22E-infected MDM, V3 sequences with at least one G-to-A
nucleotide mutation were detected at 14 and 21 days postinfec-
tion, with prevalence rates of 5.95% and 5.24% for donor 1 and
FIG 2 Replication capacities of 81.A-VifWT, 81.A-VifK22E, and 81.A-VifE45G in PBMC (A and B) and MDM (C and D) obtained from 2 different donors. PBMC
and MDM were infected with 10,000 pg p24 per 106 cells. Donor 1 and donor 2 are the two different donors of the study. Mean values for at least 3 wells for each
point are shown. Error bars indicate intraexperimental standard deviations.
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0.96% and 0.05% for donor 2 (Table 1). It is noteworthy that V3
sequences with at least one C-to-T nucleotide mutation (also re-
lated to APOBEC3 deamination events [6]) were detected in 81.A-
VifK22E-infected MDM from donor 1 at 21 days postinfection, at a
prevalence of 12.55%.
The increased genetic diversity in conjunction with attenuated
replication capacity observed with the 81.A-VifK22E mutant strain
was in line with previous studies that showed a lower plasma
viremia in HIV-1-infected patients with G-to-A-enriched provi-
ruses (21).
In PBMC and MDM, 91.3% and 100% of V3 sequences with at
least one G-to-A nucleotide mutation occurred in a GG context,
known to be the preferential target site for APOBEC3G (Table 1).
Genotypic characterization of V3 HIV-1 DNA derived from
81.A-VifK22E. The G-to-A nucleotide mutations occurring in
HIV-1 DNA from 81.A-VifK22E-infected PBMC encode amino
acid substitutions at four V3 positions in donor 1 (aa positions 15,
24, 25, and 28) and at six V3 positions in donor 2 (aa positions 15,
17, 19, 24, 28, and 29) (Fig. 3). In both donors, the G-to-A nucle-
otide mutations generated G15R, G24E, and G28R, which were
detected at prevalence rates reaching 2.73%, 1.18%, and 0.49% in
donor 1 and 6.24%, 0.53%, and 5.62% in donor 2, respectively.
TABLE 1 Number and type of V3 sequences obtained by UDPS at different times postinfection in viruses with WT or a variant Vif
Cell type and
source Virus
Day
postinfection
Total no. of
V3 sequences
No. (%) of V3 sequences with at least one change ofa:
G to A
(overall)
G to A
(in GG motif)
G to A
(in GA motif) C to T
Other
mutations
PBMC
Donor 1 81.A-VifWT 7 14,622 0 0 0 0 0
14 20,024 0 0 0 0 0
21 14,351 0 0 0 0 0
81.A-VifK22E 7 16,720 363 (2.18) 282 (77.69) 81 (22.32) 0 0
14 10,672 220 (2.07) 79 (35.91) 141 (64.1) 0 0
21 10,364 318 (3.07) 318 (100) 7 (2.21) 0 0
81.A-VifE45G 7 20,024 0 0 0 0 0
14 11,719 0 0 0 0 0
21 11,324 0 0 0 0 138 (1.22)
Donor 2 81.A-VifWT 7 27,466 0 0 0 0 0
14 22,248 0 0 0 0 0
21 23,046 0 0 0 0 0
81.A-VifK22E 7 19,323 2,026 (10.49) 2,026 (100) 242 (11.95) 0 0
14 23,345 1,485 (6.37) 1,485 (100) 124b (8.36) 0 139 (0.6)
21 24,896 2,161 (8.69) 1,811 (83.81) 51 (2.37) 0 0
81.A-VifE45G 7 20,363 0 0 0 0 0
14 17,943 0 0 0 0 0
21 15,730 0 0 0 0 0
Total 324,180 6,573 (2.03) 600 (91.3) 646 (9.83) 0 277 (0.09)
MDM
Donor 1 81.A-VifWT 14 12,229 0 0 0 0 0
21 11,056 0 0 0 0 209 (1.9)
28 4,972 0 0 0 0 0
81.A-VifK22E 14 13,872 824 (5.95) 824 (100) 0 0 0
21 10,279 538 (5.24) 538 (100) 0 1,290c (12.55) 15 (0.15)
28 5,481 0 0 0 0 0
81.A-VifE45G 14 13,690 0 0 0 0 0
21 11,861 0 0 0 0 0
28 14,433 0 0 0 0 0
Donor 2 81.A-VifWT 14 13,202 0 0 0 0 19 (0.15)
21 15,847 0 0 0 0 7 (0.05)
28 14,358 0 0 0 0 0
81.A-VifK22E 14 12,181 116 (0.96) 116 (100) 0 0 0
21 16,494 7 (0.05) 7 (100) 0 0 0
28 14,546 0 0 0 0 0
81.A-VifE45G 14 11,869 0 0 0 0 7 (0.06)
21 11,394 0 0 0 0 0
28 14,299 0 0 0 0 138 (0.97)
Total 222,063 1,485 (0.67) 1,485 (100) 0 1,290 (0.59) 395 (0.18)
a The number and prevalence of V3 sequences with at least one G-to-A mutation, with at least one C-to-T mutation, and with any other nucleotide mutations are shown. The
numbers of G-to-A V3 mutated sequences that were found in a GG or GA dinucleotide context were also determined.
b All of these G-to-A mutations in the GA context were present in the same haplotype containing G-to-A mutations in the GG context.
c A total of 97 of these C-to-T mutations were present in the same haplotype containing G-to-A mutations.
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Other amino acid substitutions induced by G-to-A mutations
were exclusively selected in donor 1 or donor 2, such as E25K
(prevalence, 1.28%) or G17S and A19T (prevalence, 0.3% and
1.4%, respectively). These prevalence rates are similar to those
observed in other in vitro studies that analyzed the emergence of
G-to-A nucleotide mutations in other regions of the HIV-1 ge-
nome (11, 12, 14, 16, 18, 19).
Similarly, in MDM, 81.A-VifK22E generated a pool of G-to-A
nucleotide mutations encoding G15R, G17S, G24E, and G28R
(Fig. 3), with a prevalence ranging from 0.58% to 2.38% in donor
1 and from 0.07% to 0.9% in donor 2. As reported in the previous
paragraph, C-to-T mutations also occurred at 21 days postinfec-
tion of MDM from donor 1 and resulted in the nonsynonymous
substitution A19V.
By haplotype analysis, the V3 amino acid substitutions G15R
and G28R frequently occurred in combination in 81.A-VifK22E-
infected PBMC, suggesting the occurrence of 1 deamination
event along the V3 region (Table 2).
V3 amino acid substitutions induced by G-to-A nucleotide
mutations and their associationwithCCR5 orCXCR4usage. (i)
In silico analyses. As a next step of this study, we evaluated the
impact of each single V3 amino acid substitution, detected in the
previous analysis, on genotypic predictions of HIV-1 tropism by
using the geno2pheno algorithm (Table 2). In this analysis, three
amino acid substitutions (A19V, G24E, and E25K) determined a
reduction of the FPR compared to that observed for 81.A-VifWT
virus (FPR, 27.70% for 81.A, 13.8% for A19V, 6.8% for G24E, and
5.0% for E25K). Among them, G24E and E25K are associated with
an FPR of 10% (classically used as a threshold to define non-
CCR5 usage) (47).
The role of A19V, G24E, and E25K (conferring a reduction in
the FPR compared to 81.A-VifWT) in modulating coreceptor us-
age was then investigated by using 251 HIV-1 subtype B RNA
samples obtained from a routine clinical practice (192 samples
reported to be CCR5 tropic and 59 samples reported to be CXCR4
tropic or dual/mixed tropic by both genotypic tropism test [FPR
FIG 3 Prevalence of the single G-to-A and C-to-T mutations detected in HIV DNA extracted from 81.AK22E-infected PBMC at 7, 14, and 21 days postinfection
and from 81.AK22E-infected MDM at 14, 21, and 28 days postinfection. Mutations present in more than 4 reads with both forward and reverse primers or in more
than 50 reads in only one sense were retained for the analysis.
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TABLE 2 V3 sequences with G-to-A mutations demonstrated via UDPS
Cell type and
donor no. Virus
Day
postinfection
No. of V3
sequencesa V3 amino acid sequenceb
G-to-A
or C-to-T
mutation(s)
Corresponding
amino acid
substitution(s)
in V3 motif
FPR
(%)c
PBMC
Donor 1 81.A-VifK22E 7 176 CTRPNNNTRKSIHIGPGRAFYTTGEIIRDIRQAHC GGA28AGA G28R in GG 43.5
106 CTRPNNNTRKSIHIRPGRAFYTTGEIIGDIRQAHC GGA15AGA G15R in GG 44.1
81 CTRPNNNTRKSIHIGPGRAFYTTGEIIEDIRQAHC GGA28GAA G28E in GG 54.4
14 136 CTRPNNNTRKSIHIGPGRAFYTTGKIIGDIRQAHC GAA25AAA E25K in GA 5
56 CTRPNNNTRKSIHIRPGRAFYTTGEIIRDIRQAHC GGA15AGA,
GGA28AGA
G15R in GG,
G28R in GG
65.4
23 CTRPNNNTRKSIHIGPGRAFYTTGEIIRDIRQAHC GGA28AGA G28R in GG 43.5
5 CTRPNNNTRKSIHIGPGRAFYTTEEIIGDIRQAHC GGA24GAA G24E in GG 6.8
21 258 CTRPNNNTRKSIHIRPGRAFYTTGEIIGDIRQAHC GGA15AGA G15R in GG 44.1
53 CTRPNNNTRKSIHIRPGRAFYTTGEIIRDIRQAHC GGA15AGA,
GGA28AGA
G15R in GG,
G28R in GG
65.4
7 CTRPNNNTRKSIHIGPGRAFYTTEEIIRDIRQAHC GGA24GAA,
GGA28AGA
G24E in GG,
G28R in GG
9.6
Donor 2 81.A-VifK22E 7 1,052 CTRPNNNTRKSIHIRPGRAFYTTGEIIGDIRQAHC GGA15AGA G15R in GG 44.1
732 CTRPNNNTRKSIHIGPGRAFYTTGEIIRDIRQAHC GGA28AGA G28R in GG 43.5
215 CTRPNNNTRKSIHIGPGRAFYTTGEIIRNIRQAHC GGA28AGA,
GAT29AAT
G28R in GG,
D29N in GG
46.7
17 CTRPNNNTRKSIHIRPGRAFYTTEEIIGDIRQAHC GGA15AGA,
GGA24GAA
G15R in GG,
G24E in GG
9.6
10 CTRPNNNTRKSIHIRPGRAFYTTGEIIRDIRQAHC GGA15AGA,
GGA28AGA
G15R in GG,
G28R in GG
65.4
14 774 CTRPNNNTRKSIHIRPGRAFYTTGEIIGDIRQAHC GGA15AGA G15R in GG 44.1
409 CTRPNNNTRKSIHIRPGRAFYTTGEIIRDIRQAHC GGA15AGA,
GGA28AGA
G15R in GG,
G28R in GG
65.4
124 CTRPNNNTRKSIHIGPGRAFYTTEEIIRDIRQAHC GGA24GAA,
GGA28AGA
G24E in GG,
G28R in GG
9.6
109 CTRPNNNTRKSIHIGPGRAFYTTGEIIRDIRQAHC GGA28AGA G28R in GG 43.5
69 CTRPNNNTRKSIHIRPSRAFYTTGEIIGDIRQAHC GGA15AGA,
GGC17AGC
G15R in GG,
G17S in GG
68.6
21 1,265 CTRPNNNTRKSIHIRPGRAFYTTGEIIGDIRQAHC GGA15AGA G15R in GG 44.1
350 CTRPNNNTRKSIHIGPGRTFYTTGEIIGDIRQAHC GCA19ACA A19T in GC 58.6
346 CTRPNNNTRKSIHIGPGRAFYTTGEIIRDIRQAHC GGA28AGA G28R in GG 43.5
149 CTRPNNNTRKSIHIRPGRAFYTTGEIIRDIRQAHC GGA15AGA,
GGA28AGA
G15R in GG,
G28R in GG
65.4
51 CTRPNNNTRKSIHIGPGRAFYTTGEIIRNIRQAHC GGA28AGA,
GAT29AAT
G28R in GG,
D29N in GG
46.7
MDM
Donor 1 81.A-VifK22E 14 566 CTRPNNNTRKSIHIRPGRAFYTTGEIIGDIRQAHC GGA15AGA G15R in GG 44.1
253 CTRPNNNTRKSIHIGPGRAFYTTGEIIRDIRQAHC GGA28AGA G28R in GG 43.5
5 CTRPNNNTRKSIHIRPGRAFYTTGEIIRDIRQAHC GGA15AGA,
GGA28AGA
G15R in GG,
G28R in GG
65.4
21 1,193 CTRPNNNTRKSIHIGPGRVFYTTGEIIGDIRQAHC GCA19GTA A19V in GT 13.8
181 CTRPNNNTRKSIHIRPGRAFYTTGEIIGDIRQAHC GGA15AGA G15R in GG 44.1
97 CTRPNNNTRKSIHIGPGRVFYTTGEIIRDIRQAHC GCA19GTA,
GGA28AGA
A19V in GT,
G28R in GG
23.6
94 CTRPNNNTRKSIHIGPSRAFYTTGEIIGDIRQAHC GGC17AGC G17S in GG 46.7
88 CTRPNNNTRKSIHIGPGRAFYTTGEIIRDIRQAHC GGA28AGA G28R in GG 43.5
78 CTRPNNNTRKSIHIRPGRAFYTTGEIIRDIRQAHC GGA15AGA,
GGA28AGA
G15R in GG,
G28R in GG
65.4
Donor 2 81.A-VifK22E 14 116 CTRPNNNTRKSIHIRPGRAFYTTGEIIGDIRQAHC GGA15AGA G15R in GG 44.1
81.A-VifK22E 21 7 CTRPNNNTRKSIHIGPGRAFYTTGEIIRDIRQAHC GGA28AGA G28R in GG 43.5
a Number of sequences obtained by UDPS.
b Amino acids shown in boldface indicate substitutions induced by the G-to-A or C-to-T mutations.
c FPRs below the cutoff of 10% are shown in bold.
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set at 10%] and the enhanced sensitivity version of the Trofile
assay). In this analysis, G24E and E25K occurred in 2% of V3
sequences from CCR5-using viruses and in 10% of V3 se-
quences from dual/pure CXCR4-tropic viruses (P 	 0.04 and
5.5e7, respectively) (Fig. 4A). Interestingly, the amino acid sub-
stitution A19V, characterized by an FPR of 13.8%, was also signif-
icantly associated with a dual/pure CXCR4 tropism (P	 1.7e4)
(Fig. 4A).
Finally, we conducted a docking analysis to investigate the ef-
fects of G24E, E25K, and A19V on the binding affinity between
gp120 and the CXCR4 or CCR5 coreceptor. We observed a re-
markable increase in CXCR4 affinity for gp120 in the presence of
either G24E or E25K (
Gbind, 510.0 and 522.0, respectively)
compared to WT (
Gbind,40.1 kcal/mol) (Fig. 4B). Accordingly
to its FPR of 13.8%, A19V was related to a slight CCR5 thermo-
dynamic disadvantage and with a CXCR4 thermodynamic advan-
tage compared with the WT (CCR5, 67.2 kcal/mol for WT
and 55.4 kcal/mol for A19V; CXCR4, 40.1 kcal/mol for WT
and55.2 kcal/mol for A19V) (Fig. 4B).
(ii) In vitro analysis. For in vitro experiments, we focused on
G24E and E25K, both of which confer an FPR of 10%. We in-
troduced these amino acid substitutions in the pure CCR5-using
virus 81.A by site-directed mutagenesis and then we evaluated
their ability to replicate in PM1 cells, which predominantly ex-
press the CCR5 coreceptor, and C8166 cells, which exclusively
express the CXCR4 coreceptor (47). 81.A and NL4.3 replicated in
PM1 and C8166 cells with a mean p24 production of 20,732.4
714 and 638,583 49,166 pg/ml at 10 days postinfection, respec-
tively. Although no p24 production was observed in C8166 cells
infected by G24E and E25K, a strong reduction (90%) of HIV-1
replication was observed in PM1 at 10 days postinfection for both
amino acid substitutions (124  7.3 and 1,585  620 pg/ml, re-
spectively). These results suggested that G24E and E25K can seri-
ously affect the ability of a pure CCR5-using virus to bind the
CCR5 coreceptor, posing the genetic bases for evolution toward a
dual or a pure CXCR4-using virus and supporting the need for
multiple amino acid substitutions in the tropism switch.
In vivo correlation between the presence of Vif-defective iso-
lates and CXCR4 usage in proviral DNA. To validate the in vitro
and structural results, we evaluated the correlation between the
presence of a partially defective Vif and the presence of CXCR4-
using proviruses in 84 HIV-1-infected patients under suppressive
HAART.
Overall, 41 Vif sequences (48.8%) carried markers of a defec-
tive Vif (stop codon and/or amino acid substitution known to
affect Vif activity) (2, 11, 14, 51, 52). In particular, at least one stop
codon was detected in 6 (7.1%) Vif sequences (at positions 90, 98,
120, 153, 170, and 174), while the following substitutions known
to affect Vif activity were detected: K22N (n 	 20; prevalence,
22.6%), K22H (n	 9; 10.7%), E45D (n	 7; 9.5%), E45Q (n	 1;
1.2%), W38G (n 	 1; 1.2%), C114G (n 	 1; 1.2%), and G138R
(n	 1; 1.2%).
The analysis of paired V3 and Vif DNA sequences showed
that proviral CXCR4-using strains have a higher probability of
having a partially defective Vif protein; in particular, a partially
defective Vif protein was observed in 61.8% of CXCR4-tropic
viruses (21/34), versus 40.0% of CCR5-tropic viruses (20/50;
P 	 0.04) (Fig. 5A).
In addition, the presence of a defective Vif correlated with a
level of total HIV-1 DNA lower than that observed in the wild type
(median [interquartile range], 1,183 [292 to 2,307] versus 2,367
[558 to 8,232]; P	 0.04), in line with a defect in viral replication
capacity (Fig. 5B).
DISCUSSION
In this study, we described an increased number of V3 sequences
that had at least one G-to-A nucleotide mutation in the presence
of suboptimal Vif activity. Some of these G-to-A nucleotide mu-
tations in V3 corresponded to amino acid substitutions (such as
G24E and E25K) that are associated with the acquisition of a ge-
notypically and phenotypically defined dual/pure CXCR4 tropism
and with an increased affinity for the CXCR4 N terminus. Their
role in conferring CXCR4 tropism is well known and was estab-
lished in several in vitro and in vivo studies (25–30, 48, 53, 54). Our
in vitro model (based on PM1 and C8166 cells) also suggests that
G24E and E25K can seriously affect the ability of pure CCR5-using
81.A to replicate in cells predominantly expressing the CCR5 co-
receptor. These amino acid substitutions might thus pose the ge-
netic bases for the evolution toward a dual/pure CXCR4 tropism.
FIG 4 (A) Combined phenotypic and genotypic tropism predictions of HIV-1
strains containing V3 amino acid substitutions induced by G-to-A nucleotide
mutations. The analysis was performed on 192 samples reported R5 tropic by
both genotypic and phenotypic tests and on 59 samples reported X4/DM
tropic by Trofile HS and X4 tropic by genotypic test (FPR set at 10%). Statis-
tically significant differences were assessed by chi-square tests of indepen-
dence. P values in bold were confirmed also after correction for multiple com-
parisons by the Benjamini and Hochberg method (70), using a false-positive
rate of 0.05. (B) Evaluation of the free energy of complexation, calculated for
all gp120 optimized complexes in the presence of both coreceptors, CCR5 and
CXCR4. 
Gbind, free energy of complexation for all gp120 optimized com-
plexes in the presence of both coreceptors CCR5 and CXCR4.
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It is conceivable that multiple amino acid substitutions are neces-
sary to confer a pure CXCR4 tropism, supporting the complex
phenomenon underlying the tropism switch.
The in vitro results were supported by the findings of an in vivo
analysis based on 84 paired V3 and Vif sequences from proviral
DNA. In this analysis, we found a significant correlation between
the presence of amino acid substitutions known to hamper Vif
activity and CXCR4 usage.
By analyzing the overall variability of the V3 region, 395 nucle-
otide substitutions, not accounting for G-to-A or C-to-T muta-
tions, were detected in a total of 222,063 V3 sequences, with a base
substitution rate of 1.8 per 105 bases. This datum is only slightly
lower than the base substitution error rate estimated for HIV-1 (3
nucleotide substitutions per 105 bases) (55). The nucleotide mu-
tations increased to 3,170 when we also considered G-to-A and
C-to-T events, with the base mutation rate increasing to 14.9 per
105 bases. These findings support the role of APOBEC3G/F-
driven mutagenesis in increasing the extent of V3 genetic variabil-
ity and in potentially facilitating viral evolution toward a dual/
pure CXCR4 tropism.
Our results are in line with previous studies that showed that,
in the presence of amino acid substitutions that hamper Vif activ-
ity, APOBEC3G/F can contribute to HIV-1 genetic diversification
(2, 10–15, 19, 56, 57). Thus, natural variability in Vif should be
taken into account in clinical studies aimed at evaluating the pos-
sible use of pharmacological modifiers of APOBEC3G/F expres-
sion as an alternative strategy to increase the natural protection
against HIV replication (58).
In our study, V3 G-to-A nucleotide mutations were detected in
the presence of the Vif amino acid substitution K22E and not in
the presence of E45G. This may reflect the different impacts of
K22E and E45G on the ability of Vif to neutralize APOBEC3G and
APOBEC3F (2). Indeed (and as also reported in the introduction),
in the presence of K22E, Vif completely loses the ability to neu-
tralize APOBEC3G (implying APOBEC3G editing of the viral ge-
nome) and retains partial activity against APOBEC3F (implying
less editing by APOBEC3F than APOBEC3G). Conversely, in the
presence of E45G, Vif retained weak activity against APOBEC3G
but completely neutralized APOBEC3F activity (2).
A smaller number of G-to-A nucleotide mutations were de-
tected in MDM than in PBMC. This can be explained by the fact
that K22E completely abrogates Vif’s ability to neutralize
APOBEC3G (predominantly expressed in PBMC) and partially
affects Vif activity to neutralize APOBEC3F (predominantly ex-
pressed in MDM) (2, 4, 18). This result also can be explained by
the fact that MDM are nondividing, terminally differentiated cells
with a smaller pool of endogenous nucleotides that in turn can
slow down the reverse transcriptase activity and, consequently,
the incorporation of G-to-A mutations by APOBEC3G (59).
Furthermore, it should be stressed that in this study we evalu-
ated the rate of deamination events in the presence of endogenous
expression levels of APOBEC3G/F. This allowed us to determine
differences in the amount of these nucleotide mutations between
donor 1 and donor 2.
However, the detection of G-to-A mutations in proviral DNA
from MDM may play a relevant pathogenic role, considering that
MDM are widely distributed in all tissues and organs and can fuse
with CD4 lymphocytes by transferring the virus to these cells
(60–62).
Understanding the driving forces leading to the emergence of
CXCR4-using strains is of lively interest. CXCR4-using viruses
generally emerge during the late phase of HIV infection (63, 64).
However, they have been found even during primary infection,
with a prevalence estimated at 3% to 6.4% by population-based
phenotyping and up to 17.2% by population-based sequencing,
and they have been to be associated with more rapid disease pro-
gression, even in the setting of primary infection (65–67).
The transmission of CXCR4-using viruses may be favored by a
FIG 5 (A) Correlation between a defective Vif gene and CXCR4 coreceptor usage. (B) Quantitative HIV-1 DNA (expressed in copies per 106 cells) in patients
infected with HIV-1 subtype B with defective Vif (Vif-def) or nondefective Vif (Vif-WT). IQR, interquartile range.
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defect in the expression of CCR5 at the cell surface, such as a 32-bp
deletion in the CCR5 gene (68). Other studies suggest that CCR5-
using viruses are selectively transmitted and that CXCR4-using
viruses emerge later through the acquisition of mutations in the
gp120 gene (69). All these hypotheses are not mutually exclusive,
and together they provide explanations for the time profile of
HIV-1 tropism during an infection. Our study suggests that the
APOBEC3G-driven mutagenesis can also play a role in this phe-
nomenon. This hypothesis is also consistent with recent in vivo
and in vitro studies (3, 31). By analyzing 26 longitudinal samples
from 10 patients, Heger et al. described an in vivo increase of
G-to-A mutations (all occurring in a GG or GA dinucleotide con-
text) coding for substitutions at positions 22, 24, and 25, which are
associated with CXCR4 usage (3). Recently, Sato et al. revealed
that APOBEC3D/F can promote the emergence of E25K, and in
turn the ability to bind the CXCR4 coreceptor (31). The emer-
gence of E25K was also observed in our study, mainly via an
APOBEC3G deamination event. Our overall findings support the
role of these enzymes in the evolution from CCR5 toward CXCR4
tropism. This may also have implications for the success of CCR5
antagonist-based therapy, as well as for the risk of disease progres-
sion.
Interestingly, Pido-Lopez et al. (69) found that the stimulation
of the CCR5 receptor with CCL3, one of its natural ligands, in-
creases the mRNA levels of APOBEC3G. It is possible that HIV
binding to the CCR5 coreceptor induces the expression of
APOBEC3G proteins, thus facilitating mutations in the corecep-
tor-relevant sites. This concept deserves further investigation.
A limitation of this study is that we have not determined if the
viruses resulting from the activity of APOBEC3G/F editing are
replication competent. We can speculate that the stable frequency
over time of G-to-A mutations detected in PBMC, cocultured
every 7 days with new PBMC from a healthy donor, can be con-
sistent with continuous replication (at a low level) of these viral
strains. Interestingly, by analyzing the gp120 regions flanking the
V3 nucleotide sequence, we detected the presence of a stop codon
at 81.A gp120 position 342 in only 4.8% and 20.5% of G-to-A
mutated sequences from PBMC and MDM infections, respec-
tively, resulting from the TGG-to-TAG mutation at the trypto-
phan position. In the remaining 95.2% and 79.5% of G-to-A mu-
tated sequences, no stop codons were found, suggesting that these
HIV-1 DNA sequences may be capable of infecting new cells. In
addition, as proposed by Mulder et al. (14), it is possible that these
G-to-A mutations have a role for replication-competent viruses in
the context of viral recombination, thus allowing for the selection
of replication-competent viruses with G-to-A mutations.
In conclusion, this study showed that APOBEC3G/F incom-
plete neutralization by single Vif mutations may seed a proviral
reservoir characterized by the presence of genetic signatures in V3
that can modulate HIV-1 tropism toward a dual/pure CXCR4
usage. These genetic signatures occur at positions known to be
critical for coreceptor usage, such as positions 24 and 25. Al-
though further studies are necessary to evaluate the replication
competence of these proviruses, this study may have implications
for the success of CCR5 antagonist-based therapy, as well as for the
risk of disease progression.
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